TMDX TransMedics Group, Inc.
USHealthcareAs of 2026-07-10 16:00
Why TMDX matters now
TransMedics Group, Inc. (TMDX) is a US stock in Healthcare. The latest InvestLog snapshot shows $71.23 with -1.33% on the session and $2.46B in market capitalization; recent performance reads 1-month +19.14% and YTD -35.23%.
The latest financial table shown here is Q1 2026, with revenue of $173.9M, net income of $7.3M, and EPS of $0.20. Investors can compare that operating picture with valuation signals such as P/E 19.35 and FCF yield 5.6%.
The latest indexable market news headline is "TransMedics Completes PAD Aviation Investment to Expand in Europe" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $124.00; recent insider activity includes Gunderson Thomas J. filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
19.35
PEG
0.04
P/B
5.48
P/S
4.28
EV/EBITDA
22.36
DCF Value
$-1,241.90
FCF Yield
5.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
59.1%
Operating Margin
14.9%
Net Margin
27.0%
ROE
41.9%
ROA
12.0%
ROIC
6.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $173.9M | $7.3M | $0.20 |
| Q4 2025 | $160.8M | $105.4M | $2.59 |
| FY 2025 | $605.5M | $190.3M | $4.87 |
| Q3 2025 | $143.8M | $24.3M | $0.66 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$121.20
Target (Median)
$124.00
Target Range
$80.00 - $142.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.88
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.